OmniAb, Inc. (OABI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.33-8.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OABI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.9% |
| Our one-year growth estimate | diamond | 9.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 5.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OABI — earnings miss
Dated 2026-03-04
Results of Operations and Financial Condition. On March 4, 2026, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie…
Why it matters: Making a profit is key for long-term success. It shows they are doing better.
Supportive ifNet income improves to less than -$7.7M.
Worry ifNet income worsens to more than -$7.7M.
Why it matters: If revenue keeps growing, it will help management's new goals. This shows strong business growth.
Supportive ifQ2 2026 revenue exceeds $14.4 million, continuing the growth trend.
Worry ifQ2 2026 revenue falls below $14.4 million, indicating a slowdown.
Why it matters: If revenue guidance goes up, it shows strong business growth.
Supportive ifManagement raises the 2026 revenue guidance to more than $36 million.
Worry ifManagement keeps or lowers the 2026 revenue guidance to under $32 million.
Why it matters: Progress in partner programs shows the value of OmniAb's technology. Successful advancements can drive future revenue.
Supportive ifNew partner programs are moving to clinical trials.
Worry ifNo new partner programs advance or existing ones regress.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$258 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $565 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,704 loss on $10,000 · 37.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A smaller net loss shows progress towards making money. This is a key goal.
Supportive ifNet loss for Q2 2026 is less than $7.7 million.
Worry ifNet loss for Q2 2026 is greater than $7.7 million.
Why it matters: More leadership changes could affect how OmniAb grows and operates.
Watch forThere is news about new key hires or promotions in the executive team.
Also watch forNo new changes in executive leadership or bad feedback on current leaders.
Why it matters: Positive net income would show a profit turnaround. This might bring in more investors.
Supportive ifNet income turns positive in the next quarterly report.
Worry ifNet income remains negative or worsens.
Why it matters: Topline data from these trials could confirm the value of OmniAb's technology and partnerships.
Supportive ifTopline data from the IMVT-1402 trial in rheumatoid arthritis shows positive results.
Worry ifTopline data from the IMVT-1402 trial shows disappointing results or delays.
Why it matters: Lower operating expenses can help make more money and improve cash flow.
Supportive ifOperating expenses drop to below $84 million for the full year.
Worry ifOperating expenses rise above $88 million for the full year.
Why it matters: Good trial results could show that OmniAb's technology works. This could help its reputation.
Supportive ifAnnouncement of positive Phase 3 trial results for JNJ-5322.
Worry ifAnnouncement of negative Phase 3 trial results for JNJ-5322.
Why it matters: Improving cash position is vital for funding operations and growth. It reflects financial health.
Supportive ifCash and equivalents at year-end reach $41 million or more.
Worry ifCash and equivalents fall below $37 million at year-end.
Why it matters: Updates on partner programs show how strong OmniAb's pipeline is and its future revenue.
Watch forGood news about new partner programs or progress in current ones.
Also watch forNo big updates or bad news about partner programs.